108 related articles for article (PubMed ID: 26026101)
1. Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report.
Weeber F; Koudijs MJ; Hoogstraat M; Besselink NJ; VAN Lieshout S; Nijman IJ; Cuppen E; Offerhaus GJ; Voest EE
Anticancer Res; 2015 Jun; 35(6):3399-403. PubMed ID: 26026101
[TBL] [Abstract][Full Text] [Related]
2. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
4. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
[TBL] [Abstract][Full Text] [Related]
5. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Starbuck KD; Drake RD; Budd GT; Rose PG
Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor.
Gennatas C; Michalaki V; Kairi PV; Kondi-Paphiti A; Voros D
World J Surg Oncol; 2012 Sep; 10():181. PubMed ID: 22943457
[TBL] [Abstract][Full Text] [Related]
8. The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis.
Liu L; Dehner C; Grandhi N; Lyu Y; Borcherding DC; Chrisinger JSA; Zhang X; Luo J; Tao Y; Parkes A; Bui NQ; Davis EJ; Milhem MM; Monga V; Weiss M; Tine BV; Hirbe AC
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360169
[TBL] [Abstract][Full Text] [Related]
9. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.
Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N
Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
[TBL] [Abstract][Full Text] [Related]
11. Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence.
Levin G; Capella MP; Meyer R; Brezinov Y; Gotlieb WH
Arch Gynecol Obstet; 2024 Jun; 309(6):2381-2386. PubMed ID: 38664269
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous perivascular epithelioid cell tumor: a clinicopathological and molecular reappraisal.
Charli-Joseph Y; Saggini A; Vemula S; Weier J; Mirza S; LeBoit PE
J Am Acad Dermatol; 2014 Dec; 71(6):1127-36. PubMed ID: 25267378
[TBL] [Abstract][Full Text] [Related]
13. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
[TBL] [Abstract][Full Text] [Related]
14. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma.
Pan CC; Chung MY; Ng KF; Liu CY; Wang JS; Chai CY; Huang SH; Chen PC; Ho DM
J Pathol; 2008 Feb; 214(3):387-93. PubMed ID: 18085521
[TBL] [Abstract][Full Text] [Related]
15. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Sanfilippo R; Jones RL; Blay JY; Le Cesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2019 Sep; 25(17):5295-5300. PubMed ID: 31217199
[TBL] [Abstract][Full Text] [Related]
16. RETROPERITONEAL PERIVASCULAR EPITHELIOID CELL NEOPLASM (PECOMA) RESPONSE TO MTOR KINASE INHIBITION. A CASE REPORT WITH LITERATURE REVIEW.
Damirov F; Menge F; Hohenberger P
Georgian Med News; 2022 Nov; (332):56-59. PubMed ID: 36701777
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous perivascular epithelioid cell tumor (PEComa): case report and world literature review of clinical and molecular characteristics.
Cohen PR; Kato SM; Erickson CP; Calame A; Kurzrock R
Dermatol Online J; 2022 Jan; 28(1):. PubMed ID: 35499412
[TBL] [Abstract][Full Text] [Related]
18. Malignant PEComa of the adrenal gland.
Lau SK
Pathol Res Pract; 2012 Feb; 208(2):113-7. PubMed ID: 22154607
[TBL] [Abstract][Full Text] [Related]
19. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
20. Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features.
Williamson SR; Bunde PJ; Montironi R; Lopez-Beltran A; Zhang S; Wang M; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Oct; 37(10):1619-26. PubMed ID: 23797724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
